Please login to the form below

Not currently logged in
Email:
Password:

DPP-4 inhibitors

This page shows the latest DPP-4 inhibitors news and features for those working in and with pharma, biotech and healthcare.

FDA won't add outcomes data to Januvia label

FDA won't add outcomes data to Januvia label

The US regulator has sent the pharma company a complete response letter for DPP-4 inhibitor Januvia (sitagliptin) and combination product Janumet (sitagliptin plus metformin) - along with extended release formulations - saying ... The DPP-4 inhibitors as

Latest news

  • AZ gets US approval for diabetes combo Qtern AZ gets US approval for diabetes combo Qtern

    Qtern is a fixed dose combination product based on the active ingredients in AZ's DPP-4 inhibitor Onglyza (saxagliptin) and SGLT2 inhibitor Farxiga/Forixiga (dapagliflozin). ... SGLT2 inhibitors remove glucose through the urine by blocking blood glucose

  • NICE backs freer use of SGLT2 inhibitors for diabetes NICE backs freer use of SGLT2 inhibitors for diabetes

    around £475 per year and are as cost-effective as DPP-4 inhibitors. ... Technology Evaluation, noting that SGLT2 inhibitors are now "an alternative to the separate group of drugs called DPP-4 inhibitors".

  • Merck drops once-weekly diabetes drug in US and EU Merck drops once-weekly diabetes drug in US and EU

    There are thought to be other issues with once-weekly administration of DPP-4 inhibitors. ... While they are intended to reduce the burden of taking pills by diabetics and improve compliance, patients can rarely benefit from drug-free days as those on DPP

  • FDA rejects AZ's diabetes combination FDA rejects AZ's diabetes combination

    DPP-4 inhibitors are already widely used in diabetes and SGLT2 inhibitors are fast gaining ground, despite some initial concerns about safety. . ... SGLT2 inhibitors remove glucose through the urine by blocking blood glucose re-absorption in the kidney,

  • Merck gets first OK for once-weekly DPP-4 inhibitor Merck gets first OK for once-weekly DPP-4 inhibitor

    and showed that the drug is as effective at controlling blood glucose as daily DPP-4 inhibitors. ... Not all are convinced of the benefit of this approach however, particularly as most patients taking DPP-4 inhibitors also take metformin.

More from news
Approximately 2 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2013 Pharma deals during April 2013

    standalone product and in combination with other drugs, including Januvia (Merck's blockbuster DPP-4 inhibitor) and metformin. ... SGLT2 inhibitors block the reabsorption of glucose by the kidney, increasing glucose excretion, and lowering blood glucose

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics